Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2014-11-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.4088/JCP.14m08992PMID 25470094
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of vilazodone on sexual function during the treatment of major depressive disorder.

  2013cited by this paper
• A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.

  2011cited by this paper
• The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.

  2011cited by this paper
• The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

  2011cited by this paper
• A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder

  2011cited by this paper
• Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

  2011cited by this paper
• Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.

  2011cited by this paper
• Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy

  2010cited by this paper
• Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.

  2010cited by this paper
• Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

  2009cited by this paper
• Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

  2009cited by this paper
• Anxious depression: Clinical features and treatment

  2009cited by this paper
• Relationship of neurotransmitters to the symptoms of major depressive disorder.

  2008cited by this paper
• Using controlled clinical trials to learn more about acute drug‐induced liver injury

  2008cited by this paper
• Rapid onset of true antidepressant action

  2007cited by this paper
• Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.

  2006cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• Major depressive disorder, antidepressants, and sexual dysfunction.

  2006cited by this paper
• Which factors influence psychiatrists' selection of antidepressants?

  2004cited by this paper
• Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate.

  2004cited by this paper
• Pattern‐mixture models with proper time dependence

  2003cited by this paper
• Is there a role for 5-HT1A agonists in the treatment of depression?

  2003cited by this paper
• Treating depression to remission.

  2003cited by this paper
• Prevalence of sexual dysfunction among newer antidepressants.

  2002cited by this paper
• SSRI Antidepressant Medications: Adverse Effects and Tolerability.

  2001cited by this paper
• The effects of antidepressants on sexual functioning in depressed patients: a review.

  2001cited by this paper
• Small sample inference for fixed effects from restricted maximum likelihood.

  1997cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Sexual dysfunction associated with selective serotonin reuptake inhibitors in adults with depression: a systematic review and meta-analysis

  2026cites this paper
• Molecular pathways linking the serotonin transporters (SERT) to depressive disorder: from mechanisms to treatments.

  2025cites this paper
• Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications

  2025influential citation
• A Comparative Study of Vilazodone and Escitalopram in Major Depressive Disorder

  2025cites this paper
• Advancing Antidepressive Agents: Drug Discovery and Polymer-Based Drug Delivery Systems for Improved Treatment Outcome

  2025cites this paper
• Exploring Synaptic Pathways in Traumatic Brain Injury: A Cross-Phenotype Genomics Approach

  2024cites this paper
• Safety and Efficacy of Vilazodone in Patients with Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomised Controlled Trials

  2024cites this paper
• Nicotine and fluoxetine alter adolescent dopamine-mediated behaviors via 5-HT1A receptor activation

  2024cites this paper
• Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability

  2023cites this paper
• A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults

  2023cites this paper
• NDT_A_279342 1175..1193

  2022influential citation
• Interactions of Apigenin and Safranal with the 5HT1A and 5HT2A Receptors and Behavioral Effects in Depression and Anxiety: A Molecular Docking, Lipid-Mediated Molecular Dynamics, and In Vivo Analysis

  2022cites this paper
• Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice

  2022influential citation
• A Systematic Review of the Psychiatric-Adverse Effects associated with the Administration of Vilazodone

  2021cites this paper
• Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant

  2020cites this paper
• Development of erectile dysfunction in men treated for major depressive disorder with selective serotonin reuptake inhibitors: a systematic review

  2020influential citation
• Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study

  2020influential citation
• A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up

  2020cites this paper
• The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations.

  2020cites this paper
• Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials.

  2020cites this paper
• Antidepressant Medications and Weight Change: A Narrative Review

  2020cites this paper
• Meta-analysis of placebo group dropout in adult antidepressant trials.

  2019cites this paper
• The Massachusetts General Hospital Guide to Depression

  2019cites this paper
• A Review of Novel Antidepressants: A Guide for Clinicians

  2019cites this paper
• Update on Sexual Dysfunction Associated with Psychotropic Medications and Its Treatment

  2019cites this paper
• Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications.

  2019cites this paper
• Review of antidepressants in clinic and active ingredients of traditional Chinese medicine targeting 5-HT1A receptors.

  2019cites this paper
• Pharmacological and non-pharmacological interventions of depression after traumatic brain injury: A systematic review.

  2019cites this paper
• Variation in analytic transparency in recent efficacy studies of antidepressant medication

  2018cites this paper
• Treatment-Resistant Depression

  2018cites this paper
• A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder

  2018cites this paper
• Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.

  2018cites this paper
• Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials

  2018cites this paper
• Advances in Pharmacotherapy of Late-Life Depression

  2018cites this paper
• Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial

  2018cites this paper
• Evaluation of vilazodone for the treatment of depressive and anxiety disorders

  2018cites this paper
• Meta-analysis: Second generation antidepressants and headache.

  2018cites this paper
• Chapter 7 New Antidepressant Medication : Benefits Versus Adverse Effects

  2018cites this paper
• Is Vilazodone Really the Answer to the Delay Associated with the Onset of Antidepressant Action of SSRIs? – A Randomised Control Trial

  2018influential citation
• Guideline to the Three New Antidepressants

  2017cites this paper
• Pharmacotherapy of major depression in late life: what is the role of new agents?

  2017cites this paper
• Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials

  2017cites this paper
• The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone

  2017cites this paper
• Assessment and management of sexual dysfunction in the context of depression

  2017cites this paper
• New Antidepressant Medication: Benefits Versus Adverse Effects

  2017cites this paper
• A review of significant pharmacokinetic drug interactions with antidepressants and their management

  2016cites this paper
• Comparative efficacy of selective serotonin reuptake inhibitors (SSRI) in treating major depressive disorder: a protocol for network meta-analysis of randomised controlled trials

  2016cites this paper
• Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial.

  2016cites this paper
• Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials

  2016cites this paper
• Vilazodone for the Treatment of Depression: An Update

  2016cites this paper
• Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials

  2016cites this paper
• Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone

  2016cites this paper
• The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder

  2016cites this paper
• Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity

  2016cites this paper
• Vortioxetine: a New Treatment for Major Depressive Disorder

  2016cites this paper
• Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.

  2016cites this paper
• Traumatic brain injury decreases serotonin transporter expression in the rat cerebrum

  2016cites this paper
• PHARMACOKINETICS IN PSYCHIATRY AND NEUROLOGY

  2015cites this paper
• Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder

  2015cites this paper
• The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly

  2015cites this paper
• Circulating microRNA-144-5p is associated with depressive disorders

  2015cites this paper
• Choosing medications for treatment-resistant depression based on mechanism of action.

  2015cites this paper
• Vilazodone: A Review in Major Depressive Disorder in Adults

  2015influential citation
• Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial

  2015cites this paper
• Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study

  2015cites this paper
• Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy

  2015cites this paper
• Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder

  2015cites this paper
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

  2015cites this paper